+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Finasteride Market by Route of Administration, Product Type, Strength, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Finasteride Market by Route of Administration, Product Type, Strength, Indication, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Finasteride Market by Route of Administration, Product Type, Strength, Indication, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5967736
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Finasteride Market grew from USD 122.88 million in 2024 to USD 126.55 million in 2025. It is expected to continue growing at a CAGR of 2.84%, reaching USD 145.44 million by 2030.

Exploring the Dynamics of the Finasteride Market

The finasteride market has evolved considerably over the past decade, driven by expanding therapeutic applications and a maturing generic landscape. Originally approved to address the symptoms of benign prostatic hyperplasia, finasteride has since become a frontline therapy for androgenic alopecia in both male and female patients. This evolution reflects a convergence of clinical validation, patient demand for noninvasive hair loss treatments, and the introduction of diverse dosage forms.

This executive summary distills the critical developments shaping the finasteride sector. It provides an overview of regulatory shifts, tariff impacts, and emerging competitive dynamics. Drawing on rigorous research methods, the summary highlights segmentation patterns, regional variations, and leading corporate strategies. Decision-makers will find actionable insights designed to inform investment priorities, optimize market entry tactics, and anticipate future growth trajectories in this rapidly transforming field.

Emerging Forces Reshaping Finasteride Adoption

Finasteride adoption is being reshaped by a series of transformative forces. Patent expirations have unlocked generic entry, triggering price competition and broadening access in key markets. Regulatory agencies in North America and Europe have updated labeling guidelines to reflect safety profiles in long-term use, reinforcing clinician confidence. Simultaneously, digital health platforms are facilitating direct-to-consumer awareness campaigns, accelerating demand among younger demographics.

On the supply side, manufacturers are innovating novel dosage forms to enhance patient adherence. Foam and solution-based topical applications are gaining traction as alternatives to traditional oral capsules and tablets, particularly among individuals seeking localized therapy with reduced systemic exposure. These innovations underscore the shifting balance between efficacy, convenience, and patient preferences, emphasizing the need for agile product strategies to capture emerging opportunities.

Assessing the Impact of US Tariffs on Finasteride Trade

In 2025, the introduction of updated tariffs on pharmaceutical imports in the United States has had a pronounced effect on the finasteride supply chain. Raw material suppliers have revised contract terms to offset higher import duties, leading to incremental cost pressures for manufacturers relying on active pharmaceutical ingredients sourced globally. As a result, production schedules have been realigned to optimize domestic procurement and mitigate tariff-induced margin erosion.

Manufacturers have responded by recalibrating pricing strategies and exploring nearshoring of key synthesis processes. Several leading firms have initiated feasibility studies to establish production capacity within the US, aiming to secure supply chain resilience and shield end users from price volatility. This tariff landscape has also spurred collaboration between local ingredient providers and generic drugmakers, fostering partnerships designed to streamline logistics and reduce import dependency. Ultimately, the 2025 tariff adjustments have catalyzed a realignment of procurement models and underscored the importance of strategic supply chain diversification.

Deep Dive into Segmentation Trends Driving Growth

Segmentation by route of administration reveals two primary channels: oral and topical. Oral formulations, encompassing capsules and tablets, continue to command significant market share due to established dosing regimens for benign prostatic hyperplasia. However, topical formats such as foam and solution are rapidly gaining acceptance among dermatology clinics, driven by patient preference for localized treatment with minimal systemic exposure.

The market’s division between branded and generic products reflects distinct competitive dynamics. Innovator brands and licensed global trademarks maintain premium positioning through established clinical reputation, whereas local and multinational generic manufacturers compete aggressively on price and accessibility. This dual structure enables diverse pricing tiers and fosters marketplace depth across therapeutic indications.

Strength-based segmentation highlights the coexistence of 1 mg and 5 mg doses, each aligned with specific clinical applications. The lower strength is predominantly prescribed for hair loss, while the higher dosage addresses prostate volume reduction, illustrating dose-dependent therapeutic positioning.

Indication-based segmentation distinguishes androgenic alopecia from benign prostatic hyperplasia. Within hair loss, male pattern baldness and female pattern hair loss represent key subsegments, each with tailored dosing strategies. The BPH category, spanning mild through moderate to severe cases, underscores variable treatment intensity requirements.

Distribution channels encompass hospital pharmacies-both public and private-online pharmacies hosted on manufacturer websites or third-party platforms, and retail outlets subdivided into chain and independent stores. Each channel exhibits unique purchasing behaviors driven by formulary access, patient convenience, and reimbursement structures.

End users range from dermatology and urology clinics to home care through self-medication, and hospitals operating in private or public settings. This broad end-user spectrum necessitates targeted engagement models to address distinct procurement processes and patient support services.

Unveiling Regional Variations in Finasteride Demand

Regional analysis of finasteride demand highlights diverging growth trajectories across major global markets. In the Americas, robust private sector investment in men’s health initiatives and streamlined regulatory pathways have sustained a leadership position. Brazil and Mexico are emerging as high-growth markets, propelled by increasing dermatologist networks and direct-to-consumer telehealth channels.

Europe, the Middle East & Africa present a heterogeneous landscape. Western Europe maintains stable consumption driven by mature reimbursement frameworks, while Eastern European markets are witnessing accelerated generic uptake as cost-containment measures intensify. In the Middle East, growing awareness of hair restoration treatments is expanding demand, though supply chain complexities in certain jurisdictions pose execution risks.

Asia-Pacific is characterized by rapidly expanding patient pools and evolving healthcare infrastructure. China and India account for a significant share of volume growth, underpinned by domestic generic production and government initiatives to enhance primary care capabilities. Markets such as Australia and Japan demonstrate steady uptake of novel topical formulations, reflecting high patient adherence standards and advanced dermatological practice settings.

Competitive Landscape of Key Finasteride Players

The competitive landscape is anchored by a blend of originator companies and established generic manufacturers. Merck & Co. continues to leverage its legacy as the innovator of finasteride, maintaining premium pricing through focused brand positioning and lifecycle management strategies. Leading generic players such as Teva and Sandoz compete on scale, deploying cost-efficient manufacturing processes and broad distribution networks to capture market share.

Regional specialists are also shaping the market by addressing local needs. In India, manufacturers such as Cipla and Dr. Reddy’s leverage extensive production capacity to serve both domestic and export markets. These entities invest in bioequivalence studies and strategic partnerships to secure formulary listings and hospital contracts. Meanwhile, niche compounding pharmacies across North America and Europe differentiate through customized topical preparations, targeting patients with specific tolerability requirements.

Collaborations between multinational and local manufacturers are forging new pathways. Licensing agreements expedite the introduction of branded generics in emerging markets, while joint ventures support technology transfer and capacity expansion. These alliances underscore the importance of adaptive commercial models to thrive amid escalating price competition and regulatory scrutiny.

Strategic Recommendations for Market Leaders

Industry leaders should prioritize diversification of dosage forms to capture evolving patient preferences for both oral and topical therapies. Investing in foam and solution development can strengthen market positioning and support premium pricing models. In parallel, forging partnerships with raw material suppliers and contract manufacturers will enhance supply chain resilience against tariff fluctuations and ingredient shortages.

Expanding presence in high-growth regions such as Latin America and Asia-Pacific demands tailored market entry strategies. Engaging with local clinical key opinion leaders and leveraging telemedicine platforms can accelerate adoption while mitigating regulatory hurdles. Companies should also explore direct-to-consumer education campaigns to build brand awareness in markets where hair restoration treatments remain nascent.

To navigate pricing pressures, firms must optimize their product portfolios across branded and generic segments. Implementing value-based contracting and patient support programs can reinforce loyalty among prescribers and end users. Finally, continuous monitoring of policy developments and proactive regulatory engagement are essential to anticipate changes that could impact market access and reimbursement dynamics.

Methodological Framework Underlying the Analysis

This analysis is underpinned by a rigorous methodology that integrates primary and secondary research. Extensive interviews were conducted with dermatologists, urologists, pharmacists, and procurement officers to capture real-world insights on prescribing trends, formulary decisions, and patient preferences. These qualitative inputs were complemented by an exhaustive review of regulatory filings, corporate annual reports, and scientific literature to ensure comprehensive coverage of market drivers and barriers.

Quantitative data points were triangulated across multiple databases, encompassing approval timelines, pricing indices, and shipment volumes. Statistical validation procedures were applied to verify consistency and identify aberrations. Regional and segment-level analyses were then synthesized to reveal cross-market patterns and competitive benchmarks. Quality control protocols, including peer reviews and editorial audits, were implemented throughout the process to maintain the highest standards of accuracy and objectivity.

Synthesizing Insights on Market Evolution

The finasteride market stands at a pivotal juncture where generic proliferation, innovative dosage forms, and shifting trade regulations converge to redefine growth pathways. Segmentation analysis underscores the critical interplay between route of administration, product type, strength, indication, distribution channel, and end-user preferences. Regional insights illuminate distinct opportunities in the Americas, Europe, Middle East & Africa, and Asia-Pacific, each shaped by unique regulatory, economic, and demographic factors.

Competitive dynamics reveal a balanced landscape of originator brands, global generic manufacturers, and regional specialists, with strategic collaborations emerging as a key mechanism to sustain growth. Actionable recommendations emphasize the need for diversified portfolios, supply chain resilience, targeted market entry, and value-driven contracting. Together, these insights form a cohesive narrative to guide stakeholders as they navigate the evolving finasteride ecosystem.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Oral
      • Capsule
      • Tablet
    • Topical
      • Foam
      • Solution
  • Product Type
    • Branded
      • Innovator Brands
      • Licensed Brands
    • Generic
      • Local Manufacturer
      • Multinational Manufacturer
  • Strength
    • 1 Mg
    • 5 Mg
  • Indication
    • Androgenic Alopecia
      • Female Pattern Hair Loss
      • Male Pattern Baldness
    • Benign Prostatic Hyperplasia
      • Mild BPH
      • Moderate To Severe BPH
  • Distribution Channel
    • Hospital Pharmacy
      • Private Hospital
      • Public Hospital
    • Online Pharmacy
      • Manufacturer Website
      • Third Party E-Retailer
    • Retail Pharmacy
      • Chain Pharmacy
      • Independent Pharmacy
  • End User
    • Clinics
      • Dermatology Clinics
      • Urology Clinics
    • Home Care
      • Self Medication
    • Hospitals
      • Private Hospitals
      • Public Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Alembic Pharmaceuticals Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Finasteride Market, by Route of Administration
8.1. Introduction
8.2. Oral
8.2.1. Capsule
8.2.2. Tablet
8.3. Topical
8.3.1. Foam
8.3.2. Solution
9. Finasteride Market, by Product Type
9.1. Introduction
9.2. Branded
9.2.1. Innovator Brands
9.2.2. Licensed Brands
9.3. Generic
9.3.1. Local Manufacturer
9.3.2. Multinational Manufacturer
10. Finasteride Market, by Strength
10.1. Introduction
10.2. 1 Mg
10.3. 5 Mg
11. Finasteride Market, by Indication
11.1. Introduction
11.2. Androgenic Alopecia
11.2.1. Female Pattern Hair Loss
11.2.2. Male Pattern Baldness
11.3. Benign Prostatic Hyperplasia
11.3.1. Mild BPH
11.3.2. Moderate to Severe BPH
12. Finasteride Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacy
12.2.1. Private Hospital
12.2.2. Public Hospital
12.3. Online Pharmacy
12.3.1. Manufacturer Website
12.3.2. Third Party E-Retailer
12.4. Retail Pharmacy
12.4.1. Chain Pharmacy
12.4.2. Independent Pharmacy
13. Finasteride Market, by End User
13.1. Introduction
13.2. Clinics
13.2.1. Dermatology Clinics
13.2.2. Urology Clinics
13.3. Home Care
13.3.1. Self Medication
13.4. Hospitals
13.4.1. Private Hospitals
13.4.2. Public Hospitals
14. Americas Finasteride Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Finasteride Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Finasteride Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Merck & Co., Inc.
17.3.2. Teva Pharmaceutical Industries Ltd.
17.3.3. Viatris Inc.
17.3.4. Sandoz International GmbH
17.3.5. Dr. Reddy's Laboratories Limited
17.3.6. Lupin Limited
17.3.7. Sun Pharmaceutical Industries Limited
17.3.8. Cipla Limited
17.3.9. Aurobindo Pharma Limited
17.3.10. Alembic Pharmaceuticals Limited
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. FINASTERIDE MARKET MULTI-CURRENCY
FIGURE 2. FINASTERIDE MARKET MULTI-LANGUAGE
FIGURE 3. FINASTERIDE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL FINASTERIDE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2030 (%)
FIGURE 12. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC FINASTERIDE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. FINASTERIDE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. FINASTERIDE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. FINASTERIDE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL FINASTERIDE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL FINASTERIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL FINASTERIDE MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL FINASTERIDE MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL FINASTERIDE MARKET SIZE, BY FOAM, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL FINASTERIDE MARKET SIZE, BY SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL FINASTERIDE MARKET SIZE, BY INNOVATOR BRANDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL FINASTERIDE MARKET SIZE, BY LICENSED BRANDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL FINASTERIDE MARKET SIZE, BY LOCAL MANUFACTURER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL FINASTERIDE MARKET SIZE, BY MULTINATIONAL MANUFACTURER, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL FINASTERIDE MARKET SIZE, BY 1 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL FINASTERIDE MARKET SIZE, BY 5 MG, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL FINASTERIDE MARKET SIZE, BY FEMALE PATTERN HAIR LOSS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL FINASTERIDE MARKET SIZE, BY MALE PATTERN BALDNESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL FINASTERIDE MARKET SIZE, BY MILD BPH, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL FINASTERIDE MARKET SIZE, BY MODERATE TO SEVERE BPH, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL FINASTERIDE MARKET SIZE, BY MANUFACTURER WEBSITE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL FINASTERIDE MARKET SIZE, BY THIRD PARTY E-RETAILER, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL FINASTERIDE MARKET SIZE, BY CHAIN PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL FINASTERIDE MARKET SIZE, BY INDEPENDENT PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL FINASTERIDE MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL FINASTERIDE MARKET SIZE, BY UROLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL FINASTERIDE MARKET SIZE, BY SELF MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL FINASTERIDE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL FINASTERIDE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 86. UNITED STATES FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 87. UNITED STATES FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED STATES FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 89. UNITED STATES FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 90. UNITED STATES FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 91. UNITED STATES FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 92. UNITED STATES FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 93. UNITED STATES FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 94. UNITED STATES FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 95. UNITED STATES FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 96. UNITED STATES FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 97. UNITED STATES FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. UNITED STATES FINASTERIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 99. CANADA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. CANADA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 101. CANADA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 102. CANADA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 103. CANADA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 104. CANADA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 105. CANADA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 106. CANADA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 107. CANADA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 108. CANADA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 109. CANADA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. CANADA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 111. CANADA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 112. CANADA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 113. CANADA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. CANADA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 115. CANADA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 116. CANADA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 117. MEXICO FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. MEXICO FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 119. MEXICO FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 120. MEXICO FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 122. MEXICO FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 123. MEXICO FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 124. MEXICO FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 125. MEXICO FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 126. MEXICO FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 127. MEXICO FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 128. MEXICO FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 129. MEXICO FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 130. MEXICO FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 131. MEXICO FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. MEXICO FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 133. MEXICO FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 134. MEXICO FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 140. BRAZIL FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 141. BRAZIL FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 142. BRAZIL FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 143. BRAZIL FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 144. BRAZIL FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 145. BRAZIL FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. BRAZIL FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 147. BRAZIL FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 148. BRAZIL FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 149. BRAZIL FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. BRAZIL FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 151. BRAZIL FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 152. BRAZIL FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 189. EUROPE, MIDDLE EAST & AFRICA FINASTERIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 190. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 192. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 194. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 196. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 198. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 200. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 202. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 204. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 208. GERMANY FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. GERMANY FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 210. GERMANY FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 211. GERMANY FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 213. GERMANY FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 214. GERMANY FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 215. GERMANY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 216. GERMANY FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 217. GERMANY FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 218. GERMANY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 219. GERMANY FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 220. GERMANY FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 221. GERMANY FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 222. GERMANY FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. GERMANY FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 224. GERMANY FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 225. GERMANY FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 226. FRANCE FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. FRANCE FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 228. FRANCE FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 229. FRANCE FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 230. FRANCE FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 231. FRANCE FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 232. FRANCE FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 233. FRANCE FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 234. FRANCE FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 235. FRANCE FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 236. FRANCE FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. FRANCE FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 238. FRANCE FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 239. FRANCE FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 240. FRANCE FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. FRANCE FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 242. FRANCE FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 243. FRANCE FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 246. RUSSIA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 247. RUSSIA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 248. RUSSIA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 249. RUSSIA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 250. RUSSIA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 251. RUSSIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 252. RUSSIA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 253. RUSSIA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 254. RUSSIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 255. RUSSIA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 256. RUSSIA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 257. RUSSIA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 258. RUSSIA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. RUSSIA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 260. RUSSIA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 261. RUSSIA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 262. ITALY FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. ITALY FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 264. ITALY FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 265. ITALY FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 266. ITALY FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 267. ITALY FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 268. ITALY FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 269. ITALY FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 270. ITALY FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 271. ITALY FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 272. ITALY FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. ITALY FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 274. ITALY FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 275. ITALY FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 276. ITALY FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ITALY FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 278. ITALY FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 279. ITALY FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 280. SPAIN FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 281. SPAIN FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 282. SPAIN FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 283. SPAIN FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. SPAIN FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 285. SPAIN FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 286. SPAIN FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 287. SPAIN FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 288. SPAIN FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 289. SPAIN FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 290. SPAIN FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. SPAIN FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 292. SPAIN FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 293. SPAIN FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 294. SPAIN FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 295. SPAIN FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 296. SPAIN FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 297. SPAIN FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 298. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 300. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 301. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 302. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 303. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 304. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 305. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 306. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 307. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 308. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 309. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 310. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 311. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 312. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 313. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 314. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 315. UNITED ARAB EMIRATES FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 316. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 317. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 318. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 319. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 320. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 321. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 322. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 323. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 324. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 325. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 326. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 327. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 328. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 329. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 330. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 331. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 332. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 333. SAUDI ARABIA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 334. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 335. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 336. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 337. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 338. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 339. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 340. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 341. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 342. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 343. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 344. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 345. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 346. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 347. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 348. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 349. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 350. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 351. SOUTH AFRICA FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 352. DENMARK FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 353. DENMARK FINASTERIDE MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 354. DENMARK FINASTERIDE MARKET SIZE, BY TOPICAL, 2018-2030 (USD MILLION)
TABLE 355. DENMARK FINASTERIDE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 356. DENMARK FINASTERIDE MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 357. DENMARK FINASTERIDE MARKET SIZE, BY GENERIC, 2018-2030 (USD MILLION)
TABLE 358. DENMARK FINASTERIDE MARKET SIZE, BY STRENGTH, 2018-2030 (USD MILLION)
TABLE 359. DENMARK FINASTERIDE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 360. DENMARK FINASTERIDE MARKET SIZE, BY ANDROGENIC ALOPECIA, 2018-2030 (USD MILLION)
TABLE 361. DENMARK FINASTERIDE MARKET SIZE, BY BENIGN PROSTATIC HYPERPLASIA, 2018-2030 (USD MILLION)
TABLE 362. DENMARK FINASTERIDE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 363. DENMARK FINASTERIDE MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2030 (USD MILLION)
TABLE 364. DENMARK FINASTERIDE MARKET SIZE, BY ONLINE PHARMACY, 2018-2030 (USD MILLION)
TABLE 365. DENMARK FINASTERIDE MARKET SIZE, BY RETAIL PHARMACY, 2018-2030 (USD MILLION)
TABLE 366. DENMARK FINASTERIDE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 367. DENMARK FINASTERIDE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 368. DENMARK FINASTERIDE MARKET SIZE, BY HOME CARE, 2018-2030 (USD MILLION)
TABLE 369. DENMARK FINASTERIDE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 370. NETHERLANDS FINASTERIDE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-20

Companies Mentioned

The companies profiled in this Finasteride market report include:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Sandoz International GmbH
  • Dr. Reddy's Laboratories Limited
  • Lupin Limited
  • Sun Pharmaceutical Industries Limited
  • Cipla Limited
  • Aurobindo Pharma Limited
  • Alembic Pharmaceuticals Limited

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages195
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 126.55 Million
Forecasted Market Value ( USD ) by 2030 $ 145.44 Million
Compound Annual Growth Rate2.8%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Congenital Adrenal Hyperplasia Treatment Market by Drug Type, Route of Administration, Formulation, End User, Age Group, Distribution Channel - Global Forecast to 2030 - Product Image

Congenital Adrenal Hyperplasia Treatment Market by Drug Type, Route of Administration, Formulation, End User, Age Group, Distribution Channel - Global Forecast to 2030

  • Report
  • 185 Pages
  • Global
From
Type 2 Diabetes Mellitus Treatment Market by Drug Class, Route Of Administration, Distribution Channel, Pricing Tier, End User, Line Of Therapy, Patient Age Group - Global Forecast to 2030 - Product Image

Type 2 Diabetes Mellitus Treatment Market by Drug Class, Route Of Administration, Distribution Channel, Pricing Tier, End User, Line Of Therapy, Patient Age Group - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030 - Product Image

Osteoporosis Drugs Market Size, Share, & Trends Analysis Report by Drug Class (Branded, Generics), Type (Bisphosphates, Parathyroid Hormone Therapy), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Thyroid Gland Disorder Treatment Market Size, Share & Trends Analysis Report By Indication (Hypothyroidism), By Drug (Levothyroxine), By Distribution Channel, By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031) - Product Image

Global Thyroid Eye Disease Treatment Market (2025 Edition): Analysis By Therapeutic Type (Monoclonal Antibodies, Corticosteroids, Vitamins, and Other Therapies), Route of Administration, Distribution Channel: Market Insights and Forecast (2021-2031)

  • Report
  • 238 Pages
  • Global
From

About the Finasteride Market

Finasteride is a drug used to treat endocrine and metabolic disorders. It is a type II 5-alpha reductase inhibitor, which works by blocking the enzyme responsible for converting testosterone to dihydrotestosterone (DHT). This helps to reduce the symptoms of conditions such as benign prostatic hyperplasia (BPH) and male pattern baldness. Finasteride is also used to treat hirsutism, a condition characterized by excessive hair growth in women. Finasteride is available in both oral and topical formulations. Oral finasteride is typically prescribed for BPH and male pattern baldness, while topical finasteride is used to treat hirsutism. Finasteride is generally well-tolerated, with few side effects. The Finasteride market is a growing one, with many companies offering products for the treatment of endocrine and metabolic disorders. Some of the major players in the market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc, and Mylan N.V. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.